Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.54 USD | -7.78% | -2.53% | -21.83% |
04-29 | Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem | CI |
03-28 | Transcript : Iterum Therapeutics plc, Q4 2023 Earnings Call, Mar 28, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.83% | 25.49M | |
+1.77% | 42.86B | |
+47.70% | 41.36B | |
+12.24% | 42.74B | |
-8.83% | 27.68B | |
+7.44% | 25.15B | |
-23.01% | 18.63B | |
+30.56% | 12.37B | |
-1.82% | 11.92B | |
+8.35% | 11.21B |
- Stock Market
- Equities
- ITRM Stock
- News Iterum Therapeutics plc
- Iterum Therapeutics : Evaluating Optimal Design for Additional Late-Stage UTI Drug Trial Ahead of Potential NDA Refiling